Aging isn't just a passive decline; it's active transcriptional damage. Junevity is betting $10M that they can reverse it by reprogramming cells at the source, moving beyond simple supplements to true therapeutic intervention.

"They aren't just slowing down the clock; they are trying to rewrite the code that runs it."

The team is lean—just 16 people—but they have raised significantly relative to their headcount ($625k per employee). This suggests heavy investment in R&D and IP generation rather than marketing fluff. Their leadership combines deep scientific expertise (Janine Sengstack, CSO) with operational scaling experience (Rob Cahill, COO).

• The 'Junevity Reset Platform' implies a reusable, scalable therapeutic engine, not just a one-off drug.
• Traffic spikes on keywords like 'junevity raise' indicate a market watching their burn rate and runway closely.
• The tech stack is surprisingly utilitarian (Squarespace, jQuery), suggesting resources are focused entirely on the lab, not the website.